Thesis (Ph.D) - University of Birmingham, Department of Immunology, Faculty of Medicine and Dentistry.
|Statement||by Hong Wang.|
Introduction. Burkitt lymphoma, a highly aggressive B lymphocyte non‐Hodgkin lymphoma, presents in extranodal and nodal sites 1 and also manifests as B cell acute lymphoblastic leukemia. 2 A characteristic c‐myc oncogene translocation between the long arm of chromosome 8 and the immunoglobulin heavy chain gene on chromosome 14 is seen in 80% of Burkitt lymphoma cases or Cited by: 3. B-cells of the high-grade non-Hodgkin lymphoma Burkitt's lymphoma (BL) overexpress survival oncoproteins, including the proviral integration site for Moloney murine leukaemia virus kinase (Pim)-1, and become apoptosis resistant. Activated death receptor CD95 after ligation with anti-CD95 monoclonal Cited by: 2. About one-half of all Burkitt lymphoma (BL) patients are younger than 40 years, and one-third belong to the adolescent and young adult (AYA) subset, defined by an age between 15 and 25–40 years. Regulation of Bcl-2 family proteins and caspases in cisplatin-treated B-lymphoma cell lines. Akata6 cells were treated with cisplatin (10 μg/ml) in the presence or absence of zVADfmk (50 μ M.
B-cell activation can eventually lead to activation-induced cell death of cancer cells and therefore support anti-cancer treatment. 10 Nevertheless, the TLR9 agonist effects vary strongly between B-cell cancer types, and the responses of B-cell lymphomas to ODN CpG show high variability. 11 Thus, the effects of CpG ODNs on B-cell. Adult Burkitt‐type lymphoma (BL) and acute lymphoblastic leukemia (B‐ALL) are rare entities accounting for 1% to 5% of non‐Hodgkin lymphomas (NHL) or ALL. 1, 2 BL and B‐ALL are composed of high‐grade rapidly proliferating small noncleaved mature B lymphoid cells with propensity for central nervous system (CNS) involvement. B‐ALL is characterized by L3 morphology according to the. There are 2 types of lymphycytes: T cells and B cells. Burkitt’s lymphoma is a fast-growing non-Hodgkin’s lymphoma that originates from B cells. Statistics on Burkitt’s lymphoma. Burkitt’s lymphoma is a relatively rare disease in Western countries, but is common in Central Africa. It makes up % of all non-Hodgkin’s Lymphoma. Programmed cell death ([PCD]) in multicellular organisms is a vital process in growth, development, and stress responses that contributes to the formation of tissues and organs. Although numerous studies have defined the molecular participants in apoptotic and [PCD] cascades, successful identification of early master regulators that target specific cells to live or die is limited.
As B cell lymphoma is closely associated with expression of Bcl-2 family proteins, several pro- and anti-apoptotic proteins were analyzed in EBV + cells with interrupted Vav1 expression. The pro-survival and pro-apoptotic Bcl-2 family proteins were examined by Western Blot for cells transduced with shCtrl or shVav1 respectively (Fig. 2A).Among those, Bim expression presented a pattern. The tumor arises from a germinal-center B cell that, in the majority of cases, has acquired a t(14;18) translocation that deregulates BCL2, a key gene in the regulation of cell death. B-cell lymphomas arise at distinct stages of cellular development and maturation, potentially influencing antigen (Ag) presentation and T-cell recognition. Burkitt lymphoma (BL) is a highly malignant B-cell tumor associated with Epstein-Barr Virus (EBV) infection. Although BL can be effectively treated in adults and children, leading to high survival rates, its ability to mask itself from the. Caspase-independent cell death may have a critical role to play in the therapeutic destruction of tumours. Recently it has been suggested that one of the mechanisms by which rituximab, a therapeutic anti-CD20 antibody, kills B cells is caspase-independent. In this study we show that rituximab can induce death in a variety of Burkitt lymphoma derived cell lines.